Oppenheimer的分析师将Nurix治疗药品的价格目标提高到30美元, Analysts from Oppenheimer raise Nurix Therapeutics' price target to $30 and maintain a "Moderate Buy" rating.

Nurix治疗(NASDAQ:NRIX)是一家临床阶段生物制药公司,从包括Oppenheimer在内的多个分析家得到正面评价,将价格目标提高到30.00美元。 Nurix Therapeutics (NASDAQ: NRIX), a clinical-stage biopharmaceutical firm, has received positive ratings from multiple analysts, including Oppenheimer, which raised its price target to $30.00. 股票目前价格为23.33美元, 市值为11亿5千万美元. The stock, currently at $23.33, has a market cap of $1.15 billion. 分析师通常将其评为"中等购买", 达成共识的目标为27.00美元. Analysts generally rate it as a "Moderate Buy" with a consensus target of $27.00. 最近的机构投资表明,人们对该公司的癌症治疗越来越有信心。 Recent institutional investments indicate growing confidence in the company’s cancer therapies.